Drug Trial Radar · NCT03333109
Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients
Last checked: Nov 19, 2026Latest source record: Oct 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
900
Actual
Start
Feb 8, 2018
Primary completion
Jan 13, 2020
Study completion Jan 13, 2020
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the efficacy and safety of AMG334 in adult patients with episodic migraine
Conditions
- Episodic Migraine
Interventions
ErenumabBiological
70 mg/mL pre-filled syringe administered subcutaneously
PlaceboOther
Matching placebo in pre-filled syringe administered subcutaneously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Monthly Migraine Days at the Last Month (Month 3) of the Double-blind Treatment Period (DBTP)Time frame: Baseline up to Month 3
Locations
81 sites in 11 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Ciudad Autonoma de Bs As, Argentina
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Belagavi, India
Novartis Investigative Site
Mumbai, India
Novartis Investigative Site
New Delhi, India
Novartis Investigative Site
Guntur, Andhra Pradesh, India
Novartis Investigative Site
Ahmedabad, Gujarat, India
Novartis Investigative Site
Bangalore, Karnataka, India
Novartis Investigative Site
Bangalore, Karnataka, India
Novartis Investigative Site
Mysore, Karnataka, India
Novartis Investigative Site
Kochi, Kerala, India
Novartis Investigative Site
Kochi, Kerala, India
Novartis Investigative Site
Kozhikode, Kerala, India
Novartis Investigative Site
Thiruvananthapuram, Kerala, India
Novartis Investigative Site
Mumbai, Maharashtra, India
Novartis Investigative Site
Mumbai, Maharashtra, India
Novartis Investigative Site
Nagpur, Maharashtra, India
Novartis Investigative Site
Nashik, Maharashtra, India
Novartis Investigative Site
Nashik, Maharashtra, India
Novartis Investigative Site
Pune, Maharashtra, India
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, India
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, India
Novartis Investigative Site
Ludhiana, Punjab, India
Novartis Investigative Site
Chennai, Tamil Nadu, India
Novartis Investigative Site
Hyderabad, Telangana, India
Novartis Investigative Site
Lucknow, Uttar Pradesh, India
Novartis Investigative Site
Dehradun, Uttarakhand, India
Novartis Investigative Site
Kolkata, West Bengal, India
Novartis Investigative Site
Kolkata, West Bengal, India
Novartis Investigative Site
Beirut, Lebanon
Novartis Investigative Site
Beirut, Lebanon
Novartis Investigative Site
Beirut, Lebanon
Novartis Investigative Site
Beirut, Lebanon
Novartis Investigative Site
El Chouf, LBN, Lebanon
Novartis Investigative Site
Kuala Lumpur, Malaysia
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.